Effect of the PIPAC on the Survival Rate of Patients With Peritoneal Carcinomatosis of Gastric Origin
NCT ID: NCT04879953
Last Updated: 2021-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
46 participants
OBSERVATIONAL
2020-02-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study
NCT04065139
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
NCT04595929
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
NCT06295094
PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer
NCT05303714
Intraperitoneal Aerosol Chemotherapy in Gastric Cancer
NCT01854255
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PIPAC CHEM
PIPAC associated with systemic chemotherapy
PIPAC with systemic chemotherapy
PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.
ONLY CHEM
systemic chemotherapy alone
Systemic chemotherapy alone
Intravenous chemotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PIPAC with systemic chemotherapy
PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.
Systemic chemotherapy alone
Intravenous chemotherapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with adenocarcinoma-type gastric non-resectable péritonéale carcinomatosis.
* Patients without metastasis other than peritoneal.
* WHO performance status \<3
* Patients treated either with PIPAC administered in alternation with systemic chemotherapy (PIPAC\_CHEM) or by systemic chemotherapy alone (ONLY\_CHEM)
* Patient informed
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Association Francaise de Chirurgie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr Catherine Arvieux
Professeur
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Arvieux
Role: PRINCIPAL_INVESTIGATOR
Grenoble Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHUGA
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PIPAC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.